|
Index | - | P/E | - | EPS (ttm) | -0.04 | Insider Own | 3.23% | Shs Outstand | 19.19M | Perf Week | -0.20% |
Market Cap | 187.57M | Forward P/E | - | EPS next Y | - | Insider Trans | -6.22% | Shs Float | 14.95M | Perf Month | 0.10% |
Income | -0.70M | PEG | - | EPS next Q | - | Inst Own | 92.60% | Short Float | 0.01% | Perf Quarter | -0.10% |
Sales | - | P/S | - | EPS this Y | - | Inst Trans | -0.09% | Short Ratio | 0.01 | Perf Half Y | -2.00% |
Book/sh | 7.56 | P/B | 1.30 | EPS next Y | - | ROA | -0.50% | Target Price | - | Perf Year | - |
Cash/sh | 0.04 | P/C | 234.47 | EPS next 5Y | - | ROE | -0.50% | 52W Range | 9.64 - 10.31 | Perf YTD | 0.31% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -4.90% | Beta | - |
Dividend % | - | Quick Ratio | 5.00 | Sales past 5Y | - | Gross Margin | - | 52W Low | 1.66% | ATR | 0.03 |
Employees | - | Current Ratio | 5.00 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 53.85 | Volatility | 0.00% 0.11% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | -866.20% | Profit Margin | - | Rel Volume | 0.93 | Prev Close | 9.80 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 171.96K | Price | 9.80 |
Recom | - | SMA20 | 0.22% | SMA50 | 0.42% | SMA200 | -2.02% | Volume | 159,987 | Change | 0.05% |
![]() |
|
![]() | ||||||||||||||||||
![]() | ||||||||||||||||||
|
||||||||||||||||||
![]() | ||||||||||||||||||
Research Alliance Corp. II does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It identifies and acquires a business, focusing on the healthcare industry, such as in biotechnology sector. Research Alliance Corp. II was incorporated in 2020 and is based in Las Vegas, Nevada. | ||||||||||||||||||
![]() | ||||||||||||||||||
![]() | ||||||||||||||||||
|
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite